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Limb deficiencies associated with amniotic bands comprise a wide range of congenital 
anomalies. The association of maternal medication and the risk of amniotic band sequence 
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(ABS) has not yet been addressed. Against this background we conducted a nationwide 
register-based case-control study. All cases with congenital limb deficiency associated with 
ABS born between 1996 and 2008 were included in the study. Five controls without limb 
deficiency matched for residency and time of conception were randomly selected from the 
Medical Birth Register. In total, 106 children with limb deficiency associated with ABS were 
identified and compared with 530 matched controls. Young maternal age (<25 years) 
increased the risk of limb deficiencies, OR 1.72 (95% CI: 1.06, 2.80). Nulliparity was also 
associated with increased risk, aOR 2.42 (95% CI: 1.52, 3.88). After adjusting for maternal age, 
pregestational diabetes, and parity, maternal use of beta blockers, aOR 24.2 (95% CI: 2.57, 
228) and progestogens, aOR 3.79 (95% CI: 1.38, 10.4) during the first trimester of pregnancy 
significantly increased the risk of limb deficiencies associated with amniotic bands. In 
conclusion, a novel association on increased risk of ABS with maternal use of progesterone or 
beta blockers during the first trimester of pregnancy was observed.  
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Amniotic band sequence or amniotic band syndrome (ABS) or amnion rupture sequence (ARS) 
is the term applied to a wide range of congenital anomalies (constriction rings associated with 
fibrous bands, limb and digital amputations, and cutaneous and visceral abnormalities) (1, 2). 
In the study of Lowry et al.and Bedard (2) amniotic bands with limb deficiency was the most 
frequent phenotype. There are two theories for the pathogenesis: the intrinsic causes (defect 
of germ plasm, vascular disruption and disturbance of threshold boundaries of morphogens 
during gastrulation) or the extrinsic causes (amniotic band rupture) (1, 3). The proposed 
pathogenesis for primary disruption of amniotic bands is that occlusion of a developing limb 
causes necrosis at the terminus, which adheres to and pulls off strips of amnion, resulting in 
mechanical damage to the fetus, such as constriction bands and clefts (4). 
 
A population-based study from Australia reported an incidence of 2.03 per 10 000 (5). This 
included middle trimester terminations and amniotic bands without limb deficiency. A South 
American group (6), on the other hand, reported birth prevalence of 0.89 per 10 000 births 
for ADAM (amniotic deformity, adhesions, mutilations). Orioli et al. (6) also reported that 11% 
of their ADAM sequence cases were stillborn and 15% died during neonatal period. 
 
Many risk factors have been associated with amniotic band sequences with or without body 
wall defects. Young maternal age has been found to be associated with ARS (4, 7). Similarly, 
early reports have also identified nulliparity as a risk factor for ABS (1, 4, 7). Werler et al. (4) 
reported increased risk with the use of aspirin for limb reduction defects accompanied by 
amniotic bands. Also, the use of acetaminophen in early pregnancy has been reported to be 
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a risk factor for ARS (7). To the best of our knowledge, this is the only published study to date 
on the association of maternal medication and the risk of ABS. 
 
The aim of this study was to explore maternal and pregnancy related risk factors for 
congenital limb deficiencies associated with amniotic bands. We hypothesized that first 




All cases (n=106) with congenital limb deficiencies associated with amniotic bands born in 
Finland between Jan 1, 1996 and Dec 31, 2008 were identified from the National Register of 
Congenital Malformations, the Medical Birth Register and the Register on the Induced 
Abortions, all maintained by the Finnish Institute for Health and Welfare. Information on 
maternal prescription medicine use was obtained from the Register on Reimbursed Drug 
Purchases and the Register on Medical Special Reimbursements (Social Insurance Institution 
of Finland). These registers receive information based on a legally compulsory announcement 
request on and have been validated confirming accurate data with high coverage (8-10).  
 
A detailed description of the data collection for congenital limb deficiencies has been given in 
previous papers (11, 12). All cases with ICD-9 codes 75XX and 65XX were identified and 
reviewed. Identified matches were checked by the principal investigators and all cases other 
than congenital limb deficiencies due to amniotic bands were excluded. Live births, stillbirths, 
and fetuses from spontaneous abortions and terminations of pregnancy due to fetal 




Five controls without limb deficiencies from the Medical Birth Register matched for residency, 
and time of conception (± 1 month) were randomly selected for each case. For the terminated 
fetuses, live-born, healthy  controls without congenital anomaly were selected.  
 
Maternal risk factors in the register were analyzed including maternal age, BMI, parity, 
smoking, documented long-term diseases from Medical Special Reimbursements (Diabetes 
Mellitus, Asthma, Psychotic Mental Conditions, Depression, Epilepsy, and Inflammatory 
Bowel Diseases), history of miscarriages, and utilization of assisted reproductive technology 
(ART). Smoking was defined as active smoking during 1st trimester. Maternal weight was 
recorded at the first prenatal visit 8–10 weeks after conception. The initial analysis on 
maternal medication was done at the 4th level of the Anatomical Therapeutic Chemical (ATC) 
Classification System by WHO. Each drug group with at least five exposed mothers was 
studied in univariate logistic regression and significant risk factors in these analyses were 
included the multivariable model. 
 
Conditional logistic regression was used to evaluate different risk factors. First, univariate 
models were programmed, and Fisher’s exact test was executed to search potential risk 
factors. Subsequently, a multivariable model was created. Odds ratios (OR) along with 
adjusted odds ratios (aOR) with 95% confidence intervals (CI) were calculated. The analyses 
were performed using SAS System, version 9.4 for Windows (SAS Institute Inc., Cary, NC, USA).  
 
The approval of the Institutional Review boards at the Finnish Institute of Health and Welfare 







There were 106 cases of congenital limb deficiencies associated with amniotic bands including 
five (4.7%) stillbirths and 38 (35.8%) elective terminations of pregnancy.  Total prevalence 
was 1.12 per 10,000 births and live birth prevalence was 0.67 per 10,000 live births. Four 
infants with ABS died during the first week of life and there was also one additional death 
during the first year of life. The perinatal mortality rate was 132 per 1,000 births and the infant 
mortality rate was 79 per 1,000 live births. 
 
The 106 cases with limb deficiency associated with amniotic bands were identified and 
compared with 530 matched controls. In univariate analyses, young maternal age (<25 years, 
OR 1.72 (95% CI: 1.06, 2.80) and nulliparity OR 2.56 (95% CI: 1.65, 3.97), were identified as 
significant potential maternal risk factors for congenital limb deficiencies associated with 
amniotic bands. Infants with ABS were more likely to be born prematurely, OR = 17.4, 95% CI 
9.62, 31.4. Other maternal risk factors were not significantly associated with increased risk 
(Table 1). Maternal illnesses were not significantly associated with increased risk of limb 
deficiencies. 
 
Multivariable analysis adjusted for maternal age, nulliparity and pregestational diabetes 
confirmed the increased risk associated with nulliparity (aOR = 2.42, 95% CI: 1.52, 3.88). The 
multivariable analysis on maternal prescription drugs was adjusted for maternal age, 
nulliparity and pregestational diabetes and beta blockers (ATC code C07A) and progestogens 
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(ATC code G03D) were both associated with significantly increased risk of ABS (aOR = 24.2, 





In this large population-based case-control study we have demonstrated a novel finding on 
the increased risk of first trimester use of beta blockers and progesterone on limb deficiencies 
associated with amniotic bands. ABS was also associated with nulliparity and young maternal 
age. 
 
Our data on exposures and outcomes were prospectively collected by the universally 
accessible healthcare system of our country. The registers used in this study were complete 
with accurate data and the coverage of the data on children with congenital limb deficiency 
associated with amniotic bands during the study years is high (8-13). The diagnosis of each 
congenital limb deficiency case associated with amniotic bands was confirmed by the 
principal investigators and the controversial cases were discussed by two experienced 
pediatric orthopedic surgeons. The case-control design was selected to identify risk factors 
for very rare clinical conditions. 
 
Orioli et al. (6) reported that maternal drug use was a risk factor to ADAM sequence. We 
found associations with beta blockers and progesterone. This risk associated with beta 
blockers was 24-fold on the limb deficiencies associated with amniotic bands. There are no 
previous reports on associations between beta blockers and limb deficiencies. Also, an 
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international cohort study found maternal beta blocker use to be safe during pregnancy with 
no increased risk of congenital malformations (14). In the literature there are reports of 
maternal pre-eclampsia and chronic hypertension in patients with limb deficiencies (15-17). 
Our findings on the beta blockers support the hypothesis that amniotic band syndrome 
associated limb deficiency might be related to changes in the fetal microvascular system (4). 
 
Current data showed an association with progestogens and limb deficiencies associated with 
amniotic bands. There are early reports on maternal use of exogenous sex hormones and 
associations of various congenital malformations including limb deficiencies (18-20). Other 
reports have not found significant associations (21). Recent prospective observational cohort 
study found no association between major birth defects and oral contraceptives (22). Most 
cases in our research had natural progestogens code which is often used with ART. Based on 
our research it is impossible to say if it is the hormone itself, the technology used, or the 
maternal and paternal factors related to subfertility that cause the positive correlation with 
congenital limb deficiencies. Previous studies have also had the same challenge (23).  
  
Several studies have reported a positive association with active smoking and amniotic band 
sequence-limb-body-wall-complex (ABS-LBWC) (4, 24, 25) and one study found significant 
positive association with secondhand smoking (26). Our results also suggested that smoking 
would be associated with increased risk, but the association was not statistically significant. 





Previous studies have reported twofold increase in the risk of ABS associated with young 
maternal age (5, 27). Werler et al. (7) observed a threefold increase in ABS among mothers 
<25 years of age. However, this association was not statistically significant. Similar, borderline 
significant results were also reported by Orioli et al. (6) Our findings support previous results 
regarding young maternal age as a risk factor for ABS. 
 
Our results were consistent with early reports regarding the increased risk of limb deficiencies 
associated with amniotic bands among nulliparous women (1, 4, 7). Besides ABS, nulliparity 
has been previously identified as a risk factor for several other birth defects including 
diaphragmatic hernia, omphalocele, and gastroschisis (28). It has been postulated, that 
biologic or environmental factors associated with nulliparity could explain these associations. 
However, the underlying mechanism remains unclear (28). 
 
In conclusion, a novel finding on the increased risk of ABS associated with maternal use of 
progestogens and beta blockers was observed. Future studies are warranted to confirm these 
associations. Early reports on the increased risk of ABS associated with nulliparity and young 
maternal age were supported by our results. 
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Maternal Age < 25 years (ref 25 – 34) 33 (31.1%) 111 (20.9%) 1.72 1.06, 2.80 
Maternal Age ≥ 35 years (ref 25 – 34) 11 (10.4%) 67 (12.6%) 0.92 0.45, 1.86 
Nulliparity 70 (66.0%) 228 (43.0%) 2.42 1.52, 3.88 
Pregestational diabetes 2 (1.9%) 2 (0.4%) 5.08 0.71, 36.5 
Maternal chronic hypertension 2 (1.9%) 2 (0.4%) 10.2 0.91, 113.6 
ART 3 (2.8%) 11 (2.1%) 2.50 0.63, 10.0 
Smoking 18 (17.0%) 90 (17.0%) 1.61 0.88, 2.94 
Multiple pregnancy 4 (3.8%) 22 (4.2%) 0.91 0.31, 2.67 
Invasive fetal investigation 4 (3.8%) 18 (3.4%) 1.46 0.46, 4.57 
Prematurity 59 (55.7%) 33 (6.2%) 17.4 9.62, 31.4 





Table 2. Multivariable analysis of maternal risk factors for congenital limb deficiencies 




Exposure Number of Events Adjusted 
Odds ratio 
95% CI 




Beta blockers (C07A) 4 (3.8%) 1 (0.2%) 24.2 2.57, 228.2 
Progestogens (G03D) 7 (6.6%) 11 (2.1%) 3.79 1.38, 10.4 
Gonadotropins (G03G)  3 (2.8%) 11 (2.1%) 1.46 0.39, 5.45 
Muscle relaxants (M03B) 2 (1.9%) 3 (0.6%) 4.39 0.36, 53.1 
